Story at-a-glance
-
In January
2020, Dr. Julie Gerberding, former director of the U.S. Centers for
Disease Control and Prevention, who after leaving the CDC became
president of Merck’s vaccine division, sold half her Merck stock options
for $9.11 million
-
Gerberding also
cashed out in 2016, when she sold $5.1 million in Merck stocks, and
2015, when she made $2.3 million. In total, Gerberding has made
$16,592,144 from her company stock options
-
Gerberding’s
former high-level ties to the CDC likely has had enormous influence over
Merck’s financial growth, considering Merck makes a majority of the
pediatric and adults vaccines recommended by the CDC
-
Red flags have
recently been raised about Merck’s HPV vaccine Gardasil, a vaccine
Gerberding promoted in a 2004 report to Congress before it was fast
tracked to licensure in 2006. The U.K. recently reported a 54% rise in
cervical cancer among 24- to 29-year-olds, the first generation to
receive the HPV vaccine
-
A January 2020
report in the Journal of the Royal Society of Medicine warns HPV vaccine
trials have not been designed to detect whether the vaccine actually
prevents cervical cancer. Trials have shown, however, that Gardasil
raises the risk of cervical cancer by 44.6% among women with a current
or previous HPV infection
-
- Read more: https://articles.mercola.com/sites/articles/archive/2020/03/06/julie-gerberding-merck.aspx?cid_source=dnl&cid_medium=email&cid_content=art1HL&cid=20200306Z1&et_cid=DM473197&et_rid=824174238
